Aug 14, 2025 01:59PM Larimar Therapeutics (LRMR) PT Lowered to $12 at Citi

Jun 23, 2025 01:29PM Citi on Larimar Therapeutics (LRMR): 'We are buyers on today’s weakness'

Apr 23, 2025 04:21AM Citizens JMP Reiterates Market Outperform Rating on Larimar Therapeutics (LRMR)

Mar 25, 2025 04:24AM Citi Reiterates Buy Rating on Larimar Therapeutics (LRMR)

Dec 16, 2024 02:23PM Citi Reiterates Buy Rating on Larimar Therapeutics (LRMR)

Oct 30, 2024 04:18PM Citi Reiterates Buy Rating on Larimar Therapeutics (LRMR), Opens 90-Day Upside Catalyst Watch

Feb 16, 2024 04:20PM Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Feb 14, 2024 06:15AM Larimar Therapeutics (LRMR) Prices 17.16M Share Offering at $8.74/sh

Feb 14, 2024 06:15AM Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Feb 13, 2024 04:19PM Larimar Therapeutics (LRMR) Announces Proposed Share Offering

Feb 13, 2024 04:18PM Larimar Therapeutics Announces Proposed Underwritten Public Offering

Nov 16, 2023 04:32PM Citi Upgrades Larimar Therapeutics (LRMR) to Buy, 'Current Valuation Shifts Risk/Reward Favorably'

Aug 31, 2023 04:05PM Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference